BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 35385784)

  • 1. pN0(i+) and pN1mi Breast Cancer: Treatment and Outcomes in Comparison With pN0 and pN1a in the Modern Era.
    Dosani M; Hamilton SN; Gondara L; Speers C; Diocee RM; Nichol A; Lohrisch C; Truong P
    Int J Radiat Oncol Biol Phys; 2022 Jul; 113(4):805-815. PubMed ID: 35385784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten-year locoregional recurrence risks in women with nodal micrometastatic breast cancer staged with axillary dissection.
    Lupe K; Truong PT; Alexander C; Speers C; Tyldesley S
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e681-8. PubMed ID: 21300456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pN0(i+) breast cancer: treatment patterns, locoregional recurrence, and survival outcomes.
    Karam I; Lesperance MF; Berrang T; Speers C; Tyldesley S; Truong PT
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):731-7. PubMed ID: 24035330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locoregional Recurrence and Survival Outcomes in Breast Cancer Treated With Modern Neoadjuvant Chemotherapy: A Contemporary Population-based Analysis.
    Murchison S; Nichol A; Speers C; Gondara L; Levasseur N; Lohrisch C; Vallieres I; Truong P
    Clin Breast Cancer; 2022 Oct; 22(7):e773-e787. PubMed ID: 35915021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of isolated tumor cells on loco-regional recurrence in breast cancer patients treated with breast-conserving treatment or mastectomy without post-mastectomy radiation therapy.
    Keruakous AR; Sadek BT; Shenouda MN; Niemierko A; Abi Raad RF; Specht M; Smith BL; Taghian AG
    Breast Cancer Res Treat; 2014 Jul; 146(2):365-70. PubMed ID: 24952906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies in locoregional management of breast cancer with low volume pN0(i+) and pN1mi nodal disease.
    Dosani M; Truong PT
    Expert Rev Anticancer Ther; 2019 Sep; 19(9):803-810. PubMed ID: 31498712
    [No Abstract]   [Full Text] [Related]  

  • 7. Negative Survival Impact of Occult Lymph Node Involvement in Small HER2-Positive Early Breast Cancer Treated by Up-Front Surgery.
    Houvenaeghel G; Cohen M; Martino M; Reyal F; Classe JM; Chauvet MP; Colombo PE; Heinemann M; Jouve E; Gimbergues P; Azuar AS; Coutant C; Gonçalves A; de Nonneville A
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Risk Factors for Locoregional Recurrence in Breast Cancer Patients with Nodal Stage N0 and N1: Who Could Benefit from Post-Mastectomy Radiotherapy?
    Jwa E; Shin KH; Lim HW; Jung SY; Lee S; Kang HS; Lee E; Park YH
    PLoS One; 2015; 10(12):e0145463. PubMed ID: 26691445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05).
    Shim SJ; Park W; Huh SJ; Choi DH; Shin KH; Lee NK; Suh CO; Keum KC; Kim YB; Ahn SD; Kim SS; Ha SW; Chie EK; Kim K; Shin HS; Kim JH; Lee HS
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):65-72. PubMed ID: 24161425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in Premenopausal Patients with HR+/HER2- Breast Cancer and Lymph Node Micrometastasis Based on the 21-Gene Recurrence Score.
    Bilani N; Patel R; Crowley F; Tiersten A
    Oncologist; 2023 Dec; 28(12):1049-1054. PubMed ID: 37682780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy.
    Truong PT; Yong CM; Abnousi F; Lee J; Kader HA; Hayashi A; Olivotto IA
    J Am Coll Surg; 2005 Jun; 200(6):912-21. PubMed ID: 15922205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk-adapted postmastectomy radiotherapy based on local-regional recurrence for T1-2N1M0 breast Cancer].
    Li M; Wang SL; Fang H; Tang Y; Chen B; Qi SN; Song YW; Liu YP; Lu NN; Li N; Tang Y; Ren H; Jin J; Li YX
    Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):841-849. PubMed ID: 29151291
    [No Abstract]   [Full Text] [Related]  

  • 14. Mastectomy alone for pT1-2 pN0-1 breast cancer patients: when postmastectomy radiotherapy is indicated.
    Leonardi MC; Scognamiglio IR; Maisonneuve P; Dicuonzo S; Rojas DP; Zerella MA; Morra A; Gerardi MA; Zaffaroni M; De Scalzi A; Girardi A; Magnoni F; Montagna E; Fodor CI; Galimberti VE; Veronesi P; Orecchia R; Pacelli R; Jereczek-Fossa BA; Corso G
    Breast Cancer Res Treat; 2021 Jul; 188(2):511-524. PubMed ID: 33905020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A positive margin is not always an indication for radiotherapy after mastectomy in early breast cancer.
    Truong PT; Olivotto IA; Speers CH; Wai ES; Berthelet E; Kader HA
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):797-804. PubMed ID: 14967436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy.
    Truong PT; Jones SO; Kader HA; Wai ES; Speers CH; Alexander AS; Olivotto IA
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):357-64. PubMed ID: 18676091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-negative breast cancer is not a contraindication for breast conservation.
    Adkins FC; Gonzalez-Angulo AM; Lei X; Hernandez-Aya LF; Mittendorf EA; Litton JK; Wagner J; Hunt KK; Woodward WA; Meric-Bernstam F
    Ann Surg Oncol; 2011 Oct; 18(11):3164-73. PubMed ID: 21947595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement.
    Colleoni M; Rotmensz N; Peruzzotti G; Maisonneuve P; Mazzarol G; Pruneri G; Luini A; Intra M; Veronesi P; Galimberti V; Torrisi R; Cardillo A; Goldhirsch A; Viale G
    J Clin Oncol; 2005 Mar; 23(7):1379-89. PubMed ID: 15735114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locoregional Management and Prognostic Factors in Breast Cancer With Ipsilateral Internal Mammary and Axillary Lymph Node Involvement.
    Andring LM; Diao K; Sun S; Patel M; Whitman GJ; Schlembach P; Arzu I; Joyner MM; Shaitelman SF; Hoffman K; Stauder MC; Smith BD; Woodward WA
    Int J Radiat Oncol Biol Phys; 2022 Jul; 113(3):552-560. PubMed ID: 35248602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement.
    Christopherson K; Lei X; Barcenas C; Buchholz TA; Garg N; Hoffman KE; Kuerer HM; Mittendorf E; Perkins G; Shaitelman SF; Smith GL; Stauder M; Strom EA; Tereffe W; Woodward WA; Smith BD
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):574-581. PubMed ID: 30851348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.